SCHEMBL1491833

SCHEMBL1491833

CCOC(=O)/C(=N\Nc1ccc(C(C)C)cc1)C(C)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ABCB1 P08183 1/20 0.46
KYAT1 Q16773 5/20 0.45
NPSR1 Q6W5P4 2/20 0.45
ATM Q13315 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
NPC1 O15118 3/20 0.44
MAPT P10636 3/20 0.44
RAB9A P51151 3/20 0.44
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPK1 P28482 1/20 0.44
GAA P10253 2/20 0.43
HPGD P15428 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HTT P42858 1/20 0.42
EPHX1 P07099 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1491836 1.00 LMNA (0.48) LMNAMEN1KMT2AABCB1KYAT1
SCHEMBL1491858 0.86 MEN1 (0.61) LMNAMEN1KMT2AABCB1KYAT1
SCHEMBL1491860 0.86 MEN1 (0.61) LMNAMEN1KMT2AABCB1KYAT1
SCHEMBL11390921 0.86 KYAT1 (0.58) LMNAMEN1KMT2AABCB1KYAT1
SCHEMBL11390894 0.86 KYAT1 (0.58) LMNAMEN1KMT2AABCB1KYAT1
SCHEMBL15047055 0.85 NPSR1 (0.48) LMNAMEN1KMT2AABCB1KYAT1
SCHEMBL15047081 0.85 NPSR1 (0.48) LMNAMEN1KMT2AABCB1KYAT1
SCHEMBL1491865 0.83 KYAT1 (0.60) LMNAMEN1KMT2AABCB1KYAT1
SCHEMBL19283212 0.83 MAPT (0.56) LMNAMEN1KMT2AABCB1KYAT1
SCHEMBL1491863 0.83 KYAT1 (0.60) LMNAMEN1KMT2AABCB1KYAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029983-A1 AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2013-01-31 US disclosed
WO-2011037985-A1 AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2011-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029983-A1 AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY MAPT, PSEN1, PSEN2 LMNA 2227/4885MEN1 2376/4885KMT2A 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.